Healthcare provider profile · identity verified

Alan L. Grove, MD

Family Practice · ROSEVILLE, CA · NPI 1124106257

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	523	202
Amlodipine Besylate	Amlodipine Besylate	444	169
Losartan Potassium	Losartan Potassium	321	118
Levothyroxine Sodium	Levothyroxine Sodium	314	105
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	254	62
Metoprolol Succinate	Metoprolol Succinate	213	80
Atenolol	Atenolol	200	74
Lisinopril	Lisinopril	199	88
Hydrochlorothiazide	Hydrochlorothiazide	198	69
Albuterol Sulfate Hfa	Albuterol Sulfate	174	85
Fluticasone Propionate	Fluticasone Propionate	171	57
Tamsulosin Hcl	Tamsulosin Hcl	147	53
Trazodone Hcl	Trazodone Hcl	139	51
Furosemide	Furosemide	134	56
Metformin Hcl Er	Metformin Hcl	134	50
Potassium Chloride	Potassium Chloride	122	45
Famotidine	Famotidine	118	43
Gabapentin	Gabapentin	116	48
Alvesco	Ciclesonide	113	52
Pantoprazole Sodium	Pantoprazole Sodium	107	38
Metoprolol Tartrate	Metoprolol Tartrate	100	43
Meloxicam	Meloxicam	94	33
Alendronate Sodium	Alendronate Sodium	91	40
Simvastatin	Simvastatin	85	37
Omeprazole	Omeprazole	83	34
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	82	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	81	34
Fluoxetine Hcl	Fluoxetine Hcl	77	33
Ibuprofen	Ibuprofen	77	29
Allopurinol	Allopurinol	73	24
Rosuvastatin Calcium	Rosuvastatin Calcium	73	30
Lovastatin	Lovastatin	60	24
Lorazepam	Lorazepam	59	27
Prednisone	Prednisone	57	42
Pregabalin	Pregabalin	57	26
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	56	suppressed
Baclofen	Baclofen	55	14
Terazosin Hcl	Terazosin Hcl	50	21
Montelukast Sodium	Montelukast Sodium	48	18
Clopidogrel	Clopidogrel Bisulfate	46	17
Clonazepam	Clonazepam	44	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	44	19
Spiriva Respimat	Tiotropium Bromide	44	18
Glipizide	Glipizide	43	13
Jardiance	Empagliflozin	43	13
Propranolol Hcl	Propranolol Hcl	42	15
Ropinirole Hcl	Ropinirole Hcl	42	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	41	17
Escitalopram Oxalate	Escitalopram Oxalate	40	17
Finasteride	Finasteride	40	16
Duloxetine Hcl	Duloxetine Hcl	38	11
Sertraline Hcl	Sertraline Hcl	37	15
Digoxin	Digoxin	35	suppressed
Metformin Hcl	Metformin Hcl	34	12
Triamcinolone Acetonide	Triamcinolone Acetonide	34	25
Warfarin Sodium	Warfarin Sodium	34	12
Alprazolam	Alprazolam	32	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	32	16
Pravastatin Sodium	Pravastatin Sodium	32	12
Wixela Inhub	Fluticasone Propion/Salmeterol	32	14
Doxycycline Monohydrate	Doxycycline Monohydrate	30	22
Tizanidine Hcl	Tizanidine Hcl	30	19
Glipizide Er	Glipizide	29	14
Hydralazine Hcl	Hydralazine Hcl	29	13
Clobetasol Propionate	Clobetasol Propionate	28	suppressed
Hydrocortisone	Hydrocortisone	28	13
Trospium Chloride	Trospium Chloride	27	12
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	26	20
Ozempic	Semaglutide	25	suppressed
Clindamycin Hcl	Clindamycin Hcl	24	11
Eliquis	Apixaban	24	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	23	20
Ipratropium Bromide	Ipratropium Bromide	23	suppressed
Acyclovir	Acyclovir	22	11
Colchicine	Colchicine	22	suppressed
Mirtazapine	Mirtazapine	22	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	22	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	21	suppressed
Oxycodone Hcl	Oxycodone Hcl	21	suppressed
Cephalexin	Cephalexin	20	15
Nifedipine Er	Nifedipine	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	19	suppressed
Sucralfate	Sucralfate	19	suppressed
Bupropion Hcl Sr	Bupropion Hcl	18	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	18	suppressed
Azithromycin	Azithromycin	17	17
Humulin N	Insulin Nph Human Isophane	17	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	16	12
Ezetimibe	Ezetimibe	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	15	15
Amoxicillin	Amoxicillin	15	13
Azelastine Hcl	Azelastine Hcl	15	suppressed
Cartia Xt	Diltiazem Hcl	15	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Carvedilol	Carvedilol	14	suppressed
Cefadroxil	Cefadroxil	14	13
Clonidine Hcl	Clonidine Hcl	14	suppressed
Fluocinonide	Fluocinonide	14	suppressed
Morphine Sulfate	Morphine Sulfate	14	suppressed
Nitroglycerin	Nitroglycerin	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Tramadol Hcl	Tramadol Hcl	14	suppressed
Atrovent Hfa	Ipratropium Bromide	13	suppressed
Breyna	Budesonide/Formoterol Fumarate	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Lidocaine-Prilocaine	Lidocaine/Prilocaine	13	suppressed
Mupirocin	Mupirocin	13	11
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	13	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Eletriptan Hbr	Eletriptan Hydrobromide	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Donepezil Hcl	Donepezil Hcl	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Morphine Sulfate Er	Morphine Sulfate	11	suppressed
Rizatriptan	Rizatriptan Benzoate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error